The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Bertram Pitt

School of Medicine

University of Michigan

Ann Arbor

USA

[email]@umich.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • School of Medicine, University of Michigan, Ann Arbor, USA. 2002 - 2012
  • Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA. 1999 - 2009
  • University of Michigan School of Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48104, USA. 2007 - 2009

References

  1. The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Pitt, B. Heart. Fail. Rev (2012) [Pubmed]
  2. Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD. Pitt, B. Nat. Rev. Cardiol (2009) [Pubmed]
  3. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much? Pitt, B. Curr. Heart. Fail. Rep (2009) [Pubmed]
  4. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. Pitt, B. Heart (2009) [Pubmed]
  5. Aldosterone blockade in patients with chronic heart failure. Pitt, B. Cardiol. Clin (2008) [Pubmed]
  6. Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease. Pitt, B. Curr. Atheroscler. Rep (2008) [Pubmed]
  7. Prehypertension. To treat, or not to treat: that is the question. Pitt, B. Am. J. Hypertens. (2007) [Pubmed]
  8. A primer on aldosterone for gynecologists/obstetricians. Pitt, B. J. Reprod. Med (2007) [Pubmed]
  9. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Pitt, B., Pitt, G.S. Circulation (2007) [Pubmed]
  10. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Pitt, B. Nature Clinical Practice. Cardiovascular Medicine (2005) [Pubmed]
  11. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Pitt, B. Mol. Cell. Endocrinol. (2004) [Pubmed]
  12. Generic drugs in cardiology: will they reduce health care costs?. Pitt, B. J. Am. Coll. Cardiol. (2004) [Pubmed]
  13. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., Gatlin, M. N. Engl. J. Med. (2003) [Pubmed]
  14. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Pitt, B., Reichek, N., Willenbrock, R., Zannad, F., Phillips, R.A., Roniker, B., Kleiman, J., Krause, S., Burns, D., Williams, G.H. Circulation (2003) [Pubmed]
  15. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. Pitt, B., Stier, C.T., Rajagopalan, S. J. Renin. Angiotensin. Aldosterone. Syst (2003) [Pubmed]
  16. Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. Pitt, B. Am. J. Hypertens. (2002) [Pubmed]
  17. New insights into the role of aldosterone in cardiorenal disease and the clinical implications. Introduction. Pitt, B. Am. Heart J. (2002) [Pubmed]
  18. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. Pitt, B., Waters, D., Brown, W.V., van Boven, A.J., Schwartz, L., Title, L.M., Eisenberg, D., Shurzinske, L., McCormick, L.S. N. Engl. J. Med. (1999) [Pubmed]
 
WikiGenes - Universities